Endohepatology Assessment in Adults at High Risk of Fatty Liver Disease
Examines whether endohepatology testing changes treatment plans in adults at high risk of MASLD.
Plain-language title generated from the registry record
Registry title: Endohepatology-Based Reclassification of Treatment Indication in High-Risk MASLD
Key facts
- Where
- Münster, GermanySee the site
Where in Germany
- University hospital MuensterMünster, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital Muenster
- Trial code
- NCT07877272
- Record updated
- 20 October 2026
- Original description
This prospective observational study evaluates whether endohepatology changes treatment indications in adults at high risk of metabolic dysfunction-associated steatotic liver disease. Non-invasive testing is followed, when indicated, by a single-session endohepatology assessment including EUS-guided shear-wave elastography, portal pressure gradient measurement and liver biopsy. The primary outcome is treatment reclassification compared with the prospectively documented non-invasive assessment.Read full original descriptionShow less
Endohepatology-Based Reclassification of Treatment Indication in High-Risk Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Prospective, Multicenter Observational Study
This prospective observational study evaluates whether endohepatology changes treatment indications in adults at high risk of metabolic dysfunction-associated steatotic liver disease. Non-invasive testing is followed, when indicated, by a single-session endohepatology assessment including EUS-guided shear-wave elastography, portal pressure gradient measurement and liver biopsy. The primary outcome is treatment reclassification compared with the prospectively documented non-invasive assessment.
Inclusion: Age 18 years or older; Written informed consent; Suspected MASLD; At least one predefined risk criterion.
Exclusion: Previous organ transplantation or TIPS; Current resmetirom therapy; HIV infection; Vascular liver disease; No evidence of MASLD; Decompensated cirrhosis; Contraindication to endoscopy, sedation, or liver biopsy; Pregnancy or breastfeeding; Inability to provide informed consent.